COPENHAGEN, Denmark, March 12, 2018 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win ...

The latest price target for IO Biotech (NASDAQ:IOBT) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $12.00 expecting IOBT to rise to within 12 months ...

IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant Rating on IO Biotech ...

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer ...

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine ...

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ...

(RTTNews) - Shares of IO Biotech, Inc. (IOBT) are up more than 21% on Friday at $10.05. There have been no company-specific news reported that could drive the stock up. The Denmark based clinical ...

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to ...